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Background: Breast cancer patients are at elevated risk of depression
during treatment, thus provoking the chance of poor clinical outcomes.
This retrospective cohort study aimed to investigate whether integrating
Chinese herbal medicines citation(CHM) into conventional cancer therapy
could decrease the risk of depression in the long-term breast cancer survivors.
Methods: A cohort of patients aged 20–70 years and with newly diagnosed
breast cancer during 2000–2008 was identified from a nationwide claims
database. In this study, we focused solely on survivors of breast cancer
at least1 year after diagnosis. After one-to-one matching for age, sex, and
baseline comorbidities, breast cancer patients who received (n = 1,450) and
did not receive (n = 1,450) CHM treatment were enrolled. The incidence
rate and hazard ratio citation(HR) for depression between the two groups
was estimated at the end of 2012. A Cox proportional hazard model was
constructed to examine the impact of the CHM use on the risk of depression.
Results: During the study period, the incidence rate of depression was
significantly lower in the treated cohort than in the untreated cohort [8.57
compared with 11.01 per 1,000 person-years citation(PYs)], and the adjusted
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HR remained significant at 0.74 (95% CI 0.58–0.94) in a Cox proportional
hazards regression model. The corresponding risk further decreasing to 43%
among those using CHM for more than 1 year.
Conclusion: Finding from this investigation indicated that the lower risk of
depression observed in breast cancer patients treated with CHM, suggesting
that CHM treatment should be considered for disease management toward
breast cancer. Yet, the optimal administered dose should be determined in
further clinical trials.
KEYWORDS

breast cancer, Chinese herbal medicines, depression, cohort study, risk

Chinese herbal medicine citation(CHM) has shown
promising results in improving the body’s ability to fight
malignant disease. Several of these herbs were further proven
to improve cognitive function through the suppression of
monoamine oxidase activity and oxidative stress as well as
the modulation of the hypothalamic-pituitary-adrenal axis
activation (Zhang et al., 2018; Ahmadi Gharaei et al., 2019).
Take use of Shao-Yao-Gan-Cao-Tang as an example, it has
been found to have a beneficial effect on reducing emotional
distress owing to its ingredients of Paeonia lactiflora Pall, and
Glycyrrhiza uralensis (Liu C. T. et al., 2017; Chen et al., 2018).
The latter ingredient even was proved to exert antidepressant
effects on depressive rat model via regulating HPA Axis and
the level of amino acids neurotransmitters (Wang et al., 2008).
In this context, these biological activities of CHM may be of
value for managing depression in patients with breast cancer.
As of now, to the best of our knowledge, no study has so
far investigated the long-term effects of CHM on depression
prevention in breast cancer patients. To address this issue,
we used administrative data to create an objective measure to
determine if adding CHM into the conventional therapy could
lower the incidence of depression among breast cancer patients.

Introduction
Depression is a chronic medical condition that impacts the
cognitive, affective and physical wellbeing of a person (Cui,
2015). Globally, depression affects approximately 350 million
people (Cross et al., 2014), and is particularly common among
people with chronic and life-threatening diseases, especially
in patients affected by cancer (Delgado-Guay et al., 2009).
Recently, the advances in treatment modalities have improved
the survival for cancer survivors; nevertheless, the higher
survival rate does not represent that they have successfully
adapted or positively coped with the cancer. In contrast, the
profound functional and visible changes resulting from such
treatments, including surgery, chemotherapy, and radiation
therapy, can insidiously lead to the onset of psychiatric disorders
throughout the cancer experience (Chan et al., 2015).
Breast cancer is the most common form of malignancy
in women, and affected patients are at a higher likelihood
of experiencing depression, a condition aggravated by the
necessity to undergo continuous life-saving treatments. After
administering their cancer-related questionnaire to 179 women
with breast cancer, Kamińska et al. (2015) found that
breast cancer surgeries contributed to a higher prevalence
of depression, reaching 64% for women who underwent
mastectomy and 52.4% for women who had breast conserving
treatment. Additionally, one recent meta-analysis of 18 studies,
representing different countries, disclosed that estimated
depression prevalence among these women ranged from 14 to
95.9%, with a pooled average of 46.83% (Ahmadi Gharaei et al.,
2019). Notably, once individuals with breast cancer develop
concomitant depression, their medical costs increased by nearly
200% (Mausbach et al., 2018). Worse yet, further aggravating
these findings, their likelihood of mortality compared to patients
with cancer alone was reported to more than double (Chan et al.,
2015). These alarming data suggest that interventions geared
toward minimizing the likelihood of depression are of utmost
importance during cancer therapy.

Frontiers in Psychology

Materials and methods
Data source and identification of
patients with breast cancer
Taiwan’s NHI program, launched in 1995, is a single-payer
government-operated compulsory health insurance program.
As of 2015, up to 99.6% of Taiwan’s population was enrolled
in the NHI program Research data for this retrospective cohort
study were obtained from the Longitudinal Health Insurance
Database citation(LHID) administered by the Ministry of
Health and Welfare. The LHID contains data on one
million beneficiaries randomly sampled from the Registry
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Based on the formerly established methods, CHM users were
identified as those who ever received CHM due to breast cancer
for more than 30 days, whereas those treated for 30 days or
less were considered to be non-CHM users (Tsai et al., 2016; Li
et al., 2019). After this algorithm, 1,451 subjects were classified
as CHM users. A comparison cohort was randomly selected
from the remaining enrollees who did not receive CHM. For
each patient receiving CHM, one patient who did not receive
CHM was selected via one-to-one propensity score matching.
The propensity score value, the predicted probability of CHM
exposure, was calculated using logistic regression on the basis
of patients’ demographics as shown in Table 1, including age,
sex, monthly income, residential area, and comorbidities. Every
CHM user was randomly matched with a non-CHM user
who had the nearest propensity score, where the difference
in the score ranged between –0.1 and + 0.1 (Austin, 2011).
Furthermore, to consider immortal time bias (Shariff et al.,
2008), the index date for the follow-up period was the date of
CHM treatment initiation or, for non-CHM users, the date of
the initial breast cancer diagnosis. All patients were followed
up to the end of 2012 to confirm depression status. The followup time, in PY, was determined by calculating the time interval
from the index date to the earliest of the following end points:
diagnosis of depression, date of withdrawal from the insurance
citation(including death), or the date of December 31, 2012.

for Beneficiaries of the NHI Research Database. The use of
multistage stratified systematic sampling ensures no significant
deviations in the distribution of sex and age between the
LHID enrollees and the general population (The National
Health Research Institutes, 2002). The claim files include
inpatient and outpatient demographics, primary and secondary
diagnoses, procedures, prescriptions, and medical expenditures.
The Ministry of Health and Welfare manages the claims data
and provides scrambled random identification numbers for
insured patients to protect their privacy. Accordingly, the
Institutional Review Board and Ethics Committee of Buddhist
Dalin Tzu Chi Hospital approved this study and waived
informed consents for all the enrollees (No. B10004021-2).
In the present study, we used the ambulatory and inpatient
data of LHID from 2000 to 2008 to identify subjects with
breast cancer and being free of depression diagnosis at
baseline. We used the International Classification of DiseasesNinth Revision-Clinical Modification (ICD-9-CM) code for
the identification of patients with breast cancer. Patients aged
20–70 years who were newly diagnosed with breast cancer
(ICD-9-CM code: 174) were considered for enrollment in
the study. To ensure the identification of new breast cancer
cases, we employed a 4-year washout period (1996–1999) to
exclude any patients who had been diagnosed with breast
cancer before entering the cohort (n = 3,512). Meanwhile, to
reduce the potential for disease misclassification, only those
with catastrophic illness certification due to breast cancer
were recruited. In Taiwan, insured persons with major chronic
conditions can apply for catastrophic illness certification that
grants exemption from co-payment. The date on which the
patient gained approval for catastrophic illness registration due
to breast cancer was considered the index date (Figure 1).

Definition of covariates
Covariates in the regression model contained the age, sex,
insured amount, urbanization level of enrollee’s residential
area, former comorbidities, and medication usage. Regarding
insured amount, it was calculated from the patients’ average
monthly income and thus, also served as an economic
index. Insured income amounts were transformed to ordinal
variables according to the ≤ New Taiwan Dollar citation(NTD)
17800, NTD 17,881–43,900, and ≥ NTD $43901. As to
the urbanization level, it was calculated according to a
published scheme that classified 359 communities in Taiwan
into seven stratums, with a higher level indicating a higher
degree of urbanization. The classification scheme included
the population density, proportion of persons with a collegelevel education or higher, proportion of elderly residents,
proportion of agricultural workers, and number of physicians
per 100,000 population. In this work, the urbanization degree
was grouped into three strata: urban (levels 1–2), suburban
(levels 3–4), and rural (levels 5–7) (Liu et al., 2006). The
influence of baseline comorbidities was considered according
to medical records during the year preceding cohort entry,
using the Charlson-Deyo Comorbidity Index (CCI) (Deyo et al.,
1992). The sum of these scores was regarded as a continuous
variable for the burden of comorbidities, with higher scores
indicating a more severe impact of these comorbidities. To

Outcome of interest
The study outcome was the first diagnosis of depression,
which included major depressive disorder (ICD-9-CM codes:
296.2 and 296.3), dysthymic disorder (ICD-9-CM code: 300.4),
and depressive disorder not elsewhere classified (ICD-9-CM
code: 311). In this study, the diagnosis of depression was
determined if patients were treated with = 3 outpatient
treatment claims or =1 hospitalization due to depression. We
then excluded those who had a prior diagnosis of depression
before the breast cancer onset (n = 94), and those followed up
for less than 1 year after diagnosis of breast cancer (n = 38).
Afterward, the final cohort included 3,380 patients.

Exposure of Chinese herbal medicines
Under the NHI program in Taiwan, only certified Chinese
medicine physicians are allowed to provide CHM treatment.

Frontiers in Psychology
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TABLE 1 Demographic data and selected comorbidities of study subjects.

Variables

Total group

Non-CHM users

CHM users

N = 2,900 (%)

N = 1,450 (%)

N = 1,450 (%)

≤50

1,725 (59.5)

854 (58.9)

871 (60.1)

>50

1,175 (40.5)

596 (41.1)

579 (39.9)

48.9 (9.6)

49.1 (9.7)

48.7 (9.6)

Low

1,241 (42.8)

617 (42.6)

624 (43.0)

Median

1,516 (52.3)

772 (53.2)

744 (51.3)

1,43 (4.9)

61 (4.2)

82 (5.7)

1,944 (67.0)

972 (67.0)

972 (67.0)

Suburban

450 (15.5)

218 (15.0)

232 (16.0)

Rural

506 (17.4)

260 (17.9)

246 (17.0)

5.6 (2.8)

5.4 (2.6)

5.7 (3.0)

0.52

Age (year)

Mean citation(SD)
Monthly income

High

0.31
0.16

0.66

Residential area
Urban

p

CCI scores
Mean citation(SD)

The mean age of the enrollees was 48.9 ± 9.6 years. The
majority of participants had monthly income level of NTD
17,881–43,900 (52.3%) and lived in urbanized areas (82.5%).
Regarding comorbidities, the mean CCI score was 5.6 (± 2.8).
No significant differences were found between two groups in
relation to age, monthly income, residential area, or CCI score
after PS matching, showing that the baseline characteristics
between two groups were comparable.
In the full cohort, 258 first episodes of depression were
identified: 150 in non-CHM users and 108 in CHM users
during the follow-up period of 13,629.51 and 12,601.35 personyears citation(PYs), respectively. The incidence of depression
was significantly lower among CHM users than non-CHM
users (8.57 vs. 11.01 per 1,000 PY, respectively) (adjusted
HR = 0.76; 95% CI 0.59–0.96) (Table 2). The use of CHM
for more than 1 year was associated with a 43% lower risk of
depression. Kaplan–Meier survival curves and log-rank analysis
showed a significant difference in survival rate free from
depression across three groups during the follow-up period
(P < 0.01) (Figure 2).
The most commonly prescribed Chinese herbal products
for breast cancer patients are summarized in Table 3. A total
of five formulas for the breast cancer treatment were found
to substantially lessen the subsequent risk of depression and
summarized in Figure 3: Ge Gen citation(Puerariae Lobatae
Radix), Xiang Fu citation(Cyperi Rhizoma), Bai-Hua-SheShe-Cao citation(Hedyotidis Herba), Shao-Yao-Gan-Cao-Tang
citation(Paeoniae Radix Alba, Glycyrrhizae Radix et Rhizoma),
and Yin-Qiao-San (Forsythiae Fructus, Lonicerae Japonicae Flos,
Platycodonis Radix, Menthae Haplocalycis Herba, Lophatheri
Herba, Glycyrrhizae Radix et Rhizoma, Schizonepetae Herba,
Sojae Semen Praeparatum, Arctii Fructus).

avoid duplicate counting, and possible over-adjustment in the
regression model, the diagnoses of relevant tumor were excluded
from the CCI score.

Statistical analysis
Data were analyzed using SAS version 9.3 software
(SAS Institute Inc., Cary, NC, United States). Distributions
of sociodemographic data and comorbidities between the
CHM users and non-CHM users were compared by using
the chi-square and Student’s t-test. Then we conducted a
Cox proportional hazards regression analysis to compute the
adjusted hazard ratio citation(HR) with 95% confidence interval
citation(CI) of risk of depression in association with CHM use,
after adjusting for age, sex, insurance premium (an indicator
of income), urbanization level, and CCI simultaneously in
the model. To test the robustness of the relationship between
CHM use and depression risk, all CHM users were divided
into two groups based on time of CHM use: (1) 31–365 days,
and (2) ≥ 366 days. The Kaplan–Meier method was used to
estimate the cumulative risk of depression in each group, and the
difference between groups was assessed using the log-rank test.
The proportional hazards assumption was examined by plotting
the log [–log (survival function)] vs. the log citation(survival
time). A P < 0.05 was considered statistically significant.

Results
Data were analyzed for CHM users (n = 1,450) and nonCHM users (n = 1,450). Demographic data are shown in Table 1.
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TABLE 2 Risk of depression for breast cancer patients with and without CHM use.

Patient group

N

Events

PYs

Incidence

Non-CHM users

1,450

150

13629.51

11.01

1

1

CHM users

1,450

108

12601.35

8.57

0.76 (0.59–0.96)

0.74 (0.58–0.94)

CHM use within 31–365 days

1,132

89

9680.75

9.19

0.82 (0.61–1.04)

0.80 (0.61–1.03)

318

19

2920.60

6.50

0.59 (0.36–0.92)

0.57 (0.34–0.92)

CHM use for more than 365 days

Crude HR (95% CI)

Adjusted HR* (95% CI)

*Model adjusted for age, urbanization level, monthly income, and CCI.

New diagnosed breast cancer cases
aged 20-70 years between 2000-2008
(N=3512)

i. Exclusion of those with depression prior to
developing breast cancer (n=94)
ii . No long-term cancer survivors (c:: 1 years

1

Those receiving
CHMs for at least
30 days (n=l45 l )

1

after diagnosis) (n=38)

Those without receiving
CHMs for at least 30
days (n=1929)

I

I

Propensity score matching at a 1:1 ratio by
demographic data and coexisting medical conditions

l

l

108 depression

150 depression events

events occurred in

occurred in 1450 Non-

1450 CHM users

CHM users

FIGURE 1

Flow chart of selection and follow-up of study subjects.

Discussion

positive therapeutic effect of CHM observed in this work
adds to the accumulating evidence suggesting that CHM
exerts antidepressant effects by modulating dysfunctional
neurotransmission (So et al., 2015). Proposed mechanisms
by which CHM use might decrease the risk of developing
depression include the inhibition of the monoamine oxidase
activity and oxidative stress, upregulation of neurotrophins, and
modulation of hypothalamic-pituitary-adrenal axis function
(Dowlati et al., 2010; Wang Y. et al., 2019).
A major contribution of this study is the identification of
specific CHM products associated with the observed lower risk
of depression in breast cancer patients. We found that three
single-product CHM commonly used to treat breast cancer were
associated with a lower sequent risk of depression, like use of Gegen, Xiang-fu, and Bai-hua-she-she-cao. A previous study using
an animal model reports that Pueraria, the principal ingredient
of Ge-gen, exerted marked anti-depressant effects by abating

In this evidence-based cohort study exploring the
relationship between CHM use and subsequent depression
risk in breast cancer patients, we found that patients receiving
CHM had a nearly 25% lower risk of depression than did
those not using CHM. Furthermore, those receiving CHM
for more than 365 days were found to have a significantly
lower risk of depression by 43%. Through the determination
of dose-response relation between an exposure citation(CHM
use) and the risk of an outcome citation(depression incident), it
may indeed support the causal association between the intensity
of CHM use and the resultant lower risk for depression among
breast cancer patients.
No previous studies have reported the long-term influence
of CHM on depression risk in breast cancer patients,
thus precluding comparison of results. Nevertheless, the
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FIGURE 2

Cumulative incidence of depression in breast cancer patients with and without receiving CHM treatment during the study period (Log-rank test,
P = 0.02).

With regard to multi-herb products, the use of Shao-YaoGan-Cao-Tang was observed to be associated with a decreased
risk of depression in our cohort. A previous study reported that
an active component of Shao-Yao-Gan-Cao-Tang decoction,
such as glycyrrhizin, affected multiple biological processes and
pathways that participate in neuron apoptosis and inflammatory
responses (Chen et al., 2018), all of which play key roles in
the pathogenesis of depression (Dowlati et al., 2010). Another
commonly used CHM product, Yin-Qiao-San, is used to
relieve external symptoms and clear pathogenic heat from the
body in clinical practice. This herbal product was proven to
prevent drug-induced pulmonary fibrosis in a mice model by
decreasing the plasma levels of inflammatory cytokines, like
TNF-α, interleukin citation(IL)-1, and IL-6 (Yeh et al., 2007);
these mediators have been implicated in the development of
depression (Dowlati et al., 2010).
As previously described in “Materials and methods” section,
the database used in this study has several strengths, including
its large sample size, the use of electronic records from a
national health insurance registry, and a uniform approach to
outcome assessment, all of which could strengthen validity of
the study findings. On top of that, the selection bias ought
to be minimized to a great extent by using data from the
NHI database, which included over 99% of insured persons

nuclear factor kappa beta (NF-κB) signaling (Chang et al., 2009).
NF-κB is a critical transcriptional regulator of inflammatory
response induction (Liu T. et al., 2017), and a decrease in such
signaling thereby decreases the vulnerability to depression.
Xiang-fu is a cytotoxic herb that inhibits cell growth and
promotes apoptosis of breast cancer cells (Park et al., 2014;
Mannarreddy et al., 2017; Simorangkir et al., 2019; Suryavanshi
et al., 2019; Wang F. et al., 2019). A recent in vivo study
by Zhou et al. (2016) showed that two new cycloartane
glycosides from the rhizomes of Xiang-fu were beneficial in
modulating the function of brain-derived neurotrophic factor in
the hippocampus, a compound known to promote synaptic
efficacy, neuronal connectivity, and neuroplasticity, which in
turn decrease the risk of depression.
Another commonly used single-herb product, Bai-HuaShe-She-Cao (Hedyotis diffusa), is commonly used to relieve
heat and toxicity in cancer patients (Zhang et al., 2017).
Recent animal experiments and human studies have shown
that the administration of Bai-Hua-She-She-Cao may markedly
suppress cancer cell proliferation and induced apoptosis by
modulating pro-inflammatory cytokines (Ye et al., 2015;
Zhang et al., 2017), which may account for its therapeutic
effect of preventing the onset of psychiatric disorders,
including depression.
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Additionally, the diagnostic inclusion of breast cancer was
further verified by the catastrophi illness certification. The NHI
of Taiwan randomly reviews the charts and audits medical
charges to verify the accuracy of claims. Despite this procedure,
we recognize that the misclassification of cases is always a
risk in database research, but this would be expected to occur
at random which would likely serve to only bias the overall
HR observed toward the null value and thus provide a more
conservative estimate of effect. Second, data used in this study
were drawn from a claim-based database and, accordingly,
no detailed clinical information regarding laboratory data,

in Taiwan. Nonetheless, several limitations of this study merit
attention. First, our findings were derived from analysis of
retrospective cohort data based on ICD-9-CM diagnostic codes.
Thus, relevant cases may have been misclassified. To improve
diagnostic accuracy and avoid overestimation of the prevalence
of cases of interests, we applied a 4-year washout period for
breast cancer, where patients with a diagnosis of breast cancer
during that period were considered prevalent and, therefore,
excluded from analyses. Medical records were confirmed by
requiring at least 3 outpatient service claims, or at least
1 inpatient hospitalization claim during the study period.

TABLE 3 Risk of depression in relation to the 10 most-used single-herb and multi-herb CHM products for participants.

Chinese herbal product

Ingredients or generic name

Functional classification

Yan-Hu-Suo

Rhizoma Corydalis

Release pain

Ge-gen

Radix Puerariae

Releases the neck and upper back muscles
Discharges measles
Anti-inflammation

Huang-Qin

Radix Scutellariae

Anti-inflammation
Anti-tumor

Dan-Shen

Salviae Miltiorrhizae Radix et Rhizoma

Improve micro-circulaiton anit-inflammation

Mai-Dong

Ophiopogonis Radix

Treat for dry mouth

Bai-Zhi

Radix Angelicae Dahuricae

Anti-inflammation and anti-cancer

Pu-Gong-Ying

Taraxaci Herba

Anti-inflammation and reduces abscesses

Xiang-Fu

Rhizoma Cyperi

Releases pain and regulates menstruation

Single-herb products

Hai-Piao-Xiao

Sepiae Endoconcha

Anti- stomach acid and release epigastric pain

Bai-Hua-She-She-Cao

Hedyotidis Herba

Clears Heat and reduces abscesses
Anti-inflammation, anti-cancer

Jia-Wei-Xiao-Yao-San

Radix Angelicae Sinensis, Radix Paeoniae Alba, Poria, Radix
Angelicae Dahuricae, Radix Bupleuri, Cortex Moutan, Gardenia
Glycerite, Radix Glycyrrhizae Preparata, Menthae Haplocalycis
Herba, Rhizoma Zingiberis Recens

Treat for anxiety and release stress
Release menstrual pain

Shu-Jing-Huo-Xue-Tang

Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma
Chuanxiong, Radix Rehmanniae, Semen Persicae, Rhizoma
Atractylodis, Poria, Radix Achyranthis Bidentatae, Radix Clematidis,
Radix Stephaniae Tetrandrae, Rhizoma et Radix Notopterygii, Radix
Saposhnikoviae, Radix Gentianae, Radix Angelicae Dahuricae,
Pericarpium Citri Reticulatae, Radix Glycyrrhizae, Rhizoma
Zingiberis Recens

Treat for neuralgia, and lumbago

Shao-Yao-Gan-Cao-Tang

Radix Paeoniae Alba, Radix Glycyrrhizae

Muscle relaxation

Yin-Qiao-San

Flos Lonicerae, Fructus Forsythiae, Radix Platycodi, Fructus Arctii,
Herba Menthae Haplocalycis, Semen Sojae Preparatum, Herba
Lophatheri, Herba Schizonepetae, Rhizoma Phragmitis, Radix
Glycyrrhizae

Anti-common cold, anti-virus, treat for acute tonsillitis and fever

Gan-Lu-Yin

Radix Rehmanniae, Radix Rehmanniae Preparata, Herba Dendrobii,
Radix Asparagi, Radix Ophiopogonis, Radix Scutellariae, Herba
Artemisiae Scopariae, Fructus Aurantii, Folium Eriobotryae, Radix
Glycyrrhizae

Treat for tomatitis and radiotherapy effects for breast cancer

Xiang-Sha-Liu-Jun-Zi-Tang

Radix Ginseng, Rhizoma Atractylodis Macrocephalae, Poria, Radix
Glycyrrhizae, Pericarpium Citri Reticulatae, Rhizoma Pinelliae
Preparatum, Fructus Amomi, Radix Aucklandiae

Treat for indigestion and for peptic ulcer and gastroenteritis

Ping-Wei-San

Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium
Citri Reticulatae, Radix Glycyrrhizae, Rhizoma Zingiberis Recens,
Fructus Jujube

Treat for peptic ulcer and gastroenteritis
Anti- gastric cancer

Ban-Xia-Xie-Xin-Tang

Rhizoma Pinelliae Preparatum, Rhizoma Zingiberis, Radix
Scutellariae, Rhizoma Coptidis, Radix Ginseng, Fructus Jujube,
Radix Glycyrrhizae

Treat for peptic ulcer and gastroenteritis
Anti- gastric cancer

Chai-Hu-Shu-Gan-Tang

Pericarpium Citri Reticulatae, Radix Bupleuri, Rhizoma
Chuanxiong, Fructus Aurantii, Radix Paeoniae Alba, Radix
Glycyrrhizae, Rhizoma Cyperi

Release abdominal pain
Anti-gastric cancer and liver cancer
Release breast distention

Suan-Zao-Ren-Tang

Semen Zizyphi Spinosae, Poria, Rhizoma Anemarrhenae, Rhizoma
Chuanxiong, Radix Glycyrrhizae

Treat for insomnia and stress

Multi-herb products

Frontiers in Psychology

07

frontiersin.org

Yang et al.

10.3389/fpsyg.2022.884337

Single-herb products

Number of prescriptions

HR*

Yan-Hu-Suo
Ge-Gen

690
633

0.66

95% CI
0.54-1.05
0.4 -0.95

Huang-Qin
Dan-Shen

601
564

I.I
0.85

0.81-1.50
0.60-111

Mai-Don_11;
Bai-Zhi

490
463

1.03
0.96

0. 3-1.46
0.66-1.38

Pu-Gong-Ying
Xian.11;-Fu

44 1
446

1.0
0.63

0. 4-1.55
0.41-0.96

Hai-Piao-Xiao
Bai-Hua-She-She-Cao

366

22

0.9
0.44

0.64-1.4
03 1-0.93

Jia-\Vei-Xiao-Yao-San
Shu-Jing-Huo-Xue-Ian_11;

826
2

0.95
0. 9

0. 2-1.25
0..58-1.08

Shao-Yao-Gan-Cao-Ian.~
Yin-Qiao-San

626
501

0.6S
0.65

0.45-0.93
0.43-0.96

Gan-Lu-Yin
Xian_11;-Sha-Liu-Jun-Zi-Ian_11;

493
484

0.91
0.92

0.63-1.30
0.63-1.32

Ping-Wei-San
Ban-Xia-Xie-Xin-Iang

466
448

0.85
0. S

0.58-115
0.49-1.IS

Chai-Hu-Shu-Gan-I an_11;
Suan-Zao-Ren-Iang

373
334

0. 7
0.

0.48-1.23
0.52-1.16

0. 5

Multi-herb products

01

0.6

Lower depiession risk

1.

IS

Higher depiession risk

FIGURE 3

Risk of depression in relation to the top 10 most-used single-herb and multi-herb products among studying participants. *Model adjusted for
age, urbanization level, monthly income and CCI.

family history, physical activity, and individual social network
relationship was available. Thus, future studies that examine the
influence of these variables are worthy of pursuit. Nevertheless,
to carefully address the confounding by indication that may
arise in this real-world comparative effectiveness study, we have
capitalized on propensity score—matched analysis to analyze
the association of CHM use with the attack of depression. For
each breast cancer patient who received CHM, one control
patient was selected by 1:1 matching, based on a propensity
score. Additionally, to more robustly assess if other treatments
may affect the finding herein, we reanalyzed the relationships
between CHM use and subsequent risk of depression by
adjusting for the utilization numbers of radiotherapy after
breast cancer onset. The rational underlying this procedure was
based on the assumption that radiotherapy for breast cancer
patients is an obligatory component of a breast-conserving
treatment modality and could cause deleterious psychological
symptoms in such a group of patients (Almasri and Rimawi,
2020; Piroth et al., 2022). The re-analysis indicated that, as
compared to breast cancer patients who did not receive CHM,
the selected breast cancer patients who received CHM still had
a significantly lower risk for depression (adjusted HR: 0.75; 95%
CI = 0.59–0.89). Third, other indicators of comorbidities, aside
from CCI score, deserve further investigation while examining

Frontiers in Psychology

the association of depression with CHM use, among such
group. Fourth, a surveillance bias might arise with this type of
exploration, as CHM users may be more likely than their control
counterparts to seek medical care. To address this issue, we
calculated the frequency of medical visits for each study subject
and adjusted this variable in the multivariate regression model.
After adjustment, findings from the reanalysis indicated that
the positive effect of CHM still remained unchanged, with an
adjusted HR of 0.79 (95% CI = 0.62–0.96), suggesting that the
number of ambulatory care visits did not appreciably affect the
conclusion herein. Fifth, due to the anonymity of identification
numbers in the database, we were unable to directly contact
the enrolled patients regarding their methods of taking CHM
products. However, nearly 95% of the dose frequencies in
Chinese herbal products are typically used for only 1 week
in clinical practice, so those who continued to receive the
same prescription for a longer period of time were, therefore,
likely to have used the prescribed medications (Lai et al., 2010).
Additionally, prescriptions for medications issued before NHI
initiation were not reflected in the data analysis in the
present study. This omission may result in underestimating the
cumulative frequencies and may have weakened the effect of the
specified CHM products. Last, although our study revealed a
substantial association between CHM use and a decreased risk of
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depression among breast cancer patients, it must be recognized
that participants were not initially randomly categorized into
users and non-users and were recruited from a single country
only. Therefore, a randomized controlled trial to test the effects
of those commonly used herbal products in treating breast
cancer patients is warranted, thus paving the way for further
personalized therapies and clinical trials on the use of adjunctive
therapy for the management of other types of malignancies.

SY-Y, C-CY, C-KW, and T-YT: conception and design.
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and T-YT: collection and assembly of data. SY-Y, HL, JS-J, S-WY,
C-KW, and T-YT: data analysis and interpretation. SY-Y, HL,
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writing. SY-Y, HL, JS-J, S-WY, H-LH, MC, M-CL, C-CY, C-KW,
and T-YT: final approval of manuscript. All authors contributed
to the article and approved the submitted version.

Conclusion
Individuals with breast cancer suffer from the mood
disorders more frequently than the general population,
especially depression. This is the first population-based survey
that rigorously evaluated the impact of CHM use on the
prevention of depression among them. We found that
integration of CHM into the conventional treatment regimen
for breast cancer for more than 2 years may reduce the
subsequent risk of depression by nearly 50%. This noteworthy
finding can provide an impetus for further research venues,
such as focusing on factors associated with utilization of
CHM, as well as in vivo studies that attempt to uncover the
main mechanisms of prescribed herbal formulae that may be
beneficial for such groups.
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